Last10K.com

Aclaris Therapeutics, Inc. (ACRS) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

Aclaris Therapeutics, Inc.

CIK: 1557746 Ticker: ACRS
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Jan. 31, 2022
Jun. 30, 2021
Document and Entity Information   
Document Type10-K  
Document Annual Reporttrue  
Document Period End DateDec. 31, 2021  
Document Transition Reportfalse  
Entity File Number001-37581  
Entity Registrant NameAclaris Therapeutics, Inc.  
Entity Incorporation, State or Country CodeDE  
Entity Tax Identification Number46-0571712  
Entity Address, Address Line One640 Lee Road, Suite 200  
Entity Address, City or TownWayne  
Entity Address, State or ProvincePA  
Entity Address, Postal Zip Code19087  
City Area Code484  
Local Phone Number324-7933  
Title of 12(b) SecurityCommon Stock, $0.00001 par value  
Trading SymbolACRS  
Security Exchange NameNASDAQ  
Entity Well-known Seasoned IssuerYes  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Interactive Data CurrentYes  
Entity Filer CategoryLarge Accelerated Filer  
Entity Small Businessfalse  
Entity Emerging Growth Companyfalse  
ICFR Auditor Attestation Flagtrue  
Entity Shell Companyfalse  
Entity Public Float  $ 914.5
Entity Common Stock, Shares Outstanding 61,275,033 
Entity Central Index Key0001557746  
Current Fiscal Year End Date--12-31  
Document Fiscal Year Focus2021  
Document Fiscal Period FocusFY  
Auditor NamePricewaterhouseCoopers LLP  
Auditor Firm ID238  
Auditor LocationPhiladelphia, Pennsylvania  
Amendment Flagfalse  

View differences made from one year to another to evaluate Aclaris Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aclaris Therapeutics, Inc..

Continue

Assess how Aclaris Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aclaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Legal
M & A
Other
Filter Subcategory:
All
Cash Flow
Expense
Product
Shares
Other
Inside Aclaris Therapeutics, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Operations And Comprehensive Loss (Parenthetical)
Consolidated Statements Of Stockholders' Equity
Consolidated Statements Of Stockholders' Equity (Parenthetical)
Accrued Expenses
Accrued Expenses (Details)
Accrued Expenses (Tables)
Agreements Related To Intellectual Property
Agreements Related To Intellectual Property (Details)
Debt
Debt (Details)
Discontinued Operations
Discontinued Operations (Details)
Discontinued Operations (Tables)
Discontinued Operations - Assets And Liabilities (Details)
Discontinued Operations - Loss (Details)
Fair Value Of Financial Assets And Liabilities
Fair Value Of Financial Assets And Liabilities (Details)
Fair Value Of Financial Assets And Liabilities (Tables)
Fair Value Of Financial Assets And Liabilities - By Type (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Deferred Assets And Liabilities, Cfds (Details)
Income Taxes - Rate Reconciliation (Details)
Income Taxes - Valuation Allowance And Unrecognized Tax Benefits (Details)
Intangible Assets
Intangible Assets (Details)
Intangible Assets (Tables)
Intangible Assets - Future Amortization Expenses (Details)
Leases
Leases (Details)
Leases (Tables)
Leases - Future Maturities Of Lease Liabilities (Details)
Leases - Lease Costs (Details)
Leases - Supplemental Information Related To Operating And Finance Leases (Details)
Legal Proceedings
Legal Proceedings (Details)
Net Loss Per Share
Net Loss Per Share (Details)
Net Loss Per Share (Tables)
Net Loss Per Share - Anti-Dilution (Details)
Organization And Nature Of Business
Organization And Nature Of Business (Details)
Property And Equipment, Net
Property And Equipment, Net (Details)
Property And Equipment, Net (Tables)
Related Party Transactions
Related Party Transactions (Details)
Restructuring Charges
Restructuring Charges (Details)
Retirement Savings Plan
Retirement Savings Plan (Details)
Rhofade Disposition
Rhofade Disposition - Amount Paid For Assets Acquired (Details)
Segment Information
Segment Information (Details)
Segment Information (Tables)
Stock-Based Awards
Stock-Based Awards (Details)
Stock-Based Awards (Tables)
Stock-Based Awards - Compensation (Details)
Stock-Based Awards - Option Activity (Details)
Stock-Based Awards - Rsus (Details)
Stockholders' Equity
Stockholders' Equity (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Goodwill (Details)
Summary Of Significant Accounting Policies - Property And Equipment (Details)
Summary Of Significant Accounting Policies - Segments (Details)
Summary Of Significant Accounting Policies - Stock-Based Compensation And Concentration Of Credit Risk And Of Significant Suppliers (Details)
Ticker: ACRS
CIK: 1557746
Form Type: 10-K Annual Report
Accession Number: 0001558370-22-001838
Submitted to the SEC: Thu Feb 24 2022 7:32:16 AM EST
Accepted by the SEC: Thu Feb 24 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/acrs/0001558370-22-001838.htm